21 October 2021 - BEAM Alliance

How the EU Pharmaceutical Strategy could help prevent the next pandemic

Video recordings of BEAM’s Roundtable. Discussion with EC officials and experts on the AMR initiatives of the EU Pharmaceutical Strategy.

27 September 2021 - BEAM Alliance

BEAM Alliance wants HERA to effectively support R&D in antimicrobial resistance

BEAM Alliance welcomes the HERA proposal but urges EU Member States to recognise the importance of early-stage support for Research…

17 November 2021 - BEAM Alliance

20 research, medical and pharmaceutical organizations call on G7 to step up action against antibiotic resistance

20 national and international organisations from academia, healthcare, global health and the pharmaceutical industry appealed today to G7 governments to…

24 November 2021 - BEAM Alliance

AMR: The life of innovative SMEs

WAAW 2021. We take you behind the scenes. This series of comics illustrates the life of SMEs innovating in the…

31 January 2022 - BEAM Alliance

Towards a functioning AMR market: 4 pillars for a PULL incentive in Europe

In its latest position paper, BEAM Alliance proposes 4 pillars to design an efficient PULL incentive for AMR in Europe.

24 November 2022 - BEAM Alliance

BEAM Alliance supported the Antimicrobial Resistance campaign within the Guardian and online

BEAM Alliance calls for an effective PULL mechanism to fix the AMR market failure.

BEAM News
Member News
Events

Latest news of BEAM Alliance

24 November 2022 - BEAM Alliance

BEAM Alliance supported the Antimicrobial Resistance campaign within the Guardian and online

BEAM Alliance calls for an effective PULL mechanism to fix the AMR market failure.

21 November 2022 - BEAM Alliance

BEAM Alliance: Building the right PULL incentive for Europe

BEAM Alliance calls for an effective PULL mechanism to fix the AMR market failure.

31 January 2022 - BEAM Alliance

Towards a functioning AMR market: 4 pillars for a PULL incentive in Europe

In its latest position paper, BEAM Alliance proposes 4 pillars to design an efficient PULL incentive for AMR in Europe.

25 November 2021 - BEAM Alliance

Antimicrobial Resistance Campaign 2021

Antimicrobial Resistance Campaign 2021. The needs of SMEs must be considered when reshaping the regulatory framework in AMR innovation.

24 November 2021 - BEAM Alliance

AMR: The life of innovative SMEs

WAAW 2021. We take you behind the scenes. This series of comics illustrates the life of SMEs innovating in the…

17 November 2021 - BEAM Alliance

20 research, medical and pharmaceutical organizations call on G7 to step up action against antibiotic resistance

20 national and international organisations from academia, healthcare, global health and the pharmaceutical industry appealed today to G7 governments to…

page 1/6

Tweets by alliancebeam

View twitter feed

Latest news of BEAM Members

28 November 2022 - Nabriva Therapeutics GmbH

Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

The Phase 1 trial is an open-label, randomized, single-dose, crossover study to assess the safety and pharmacokinetics of oral (600…

15 November 2022 - Destiny Pharma plc

Destiny Pharma: XF-73 Dermal infection project advances into clinically enabling safety study with US Government’s NIAID

XF-73 is the lead drug candidate from Destiny Pharma's XF platform, initially being developed for the prevention of post-surgical staphylococcal…

24 October 2022 - Basilea

Basilea: ERADICATE phase 3 study results highlight the potential role of ceftobiprole in the treatment of Staphylococcus aureus bacteremia (SAB)

Ceftobiprole medocaril, the prodrug of the active moiety ceftobiprole, is a cephalosporin antibiotic for intravenous administration, with rapid bactericidal activity…

17 October 2022 - GARDP Foundation

Germany and other funders pledge support to GARDP to ramp up efforts in countering antibiotic resistance

The Global Antibiotic Research and Development Partnership (GARDP) is a not-for-profit organization based in Switzerland developing new treatments for drug-resistant…

13 October 2022 - Summit Therapeutics plc

Summit Therapeutics to Present Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022

The oral presentation, entitled “Ri-CoDIFy - A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ridinilazole…

13 October 2022 - Basilea

Basilea announces late breaking presentation on the successfully completed ERADICATE phase 3 study with ceftobiprole in Staphylococcus aureus bacteremia (SAB) at IDWeek 2022

Ceftobiprole medocaril, the prodrug of the active moiety ceftobiprole, is a cephalosporin antibiotic for intravenous administration, with rapid bactericidal activity…

page 1/45

Events

16 March 2023

7th AMR Conference

The AMR conference is the one-stop-shop for all AMR stakeholders from industry, SMEs, start-ups, big pharma, academia, clinics, regulatory bodies,…

09 January 2023

Biotech Showcase™ 2023—15th Annual International Partnering Conference

Biotech Showcase™ is an investor and networking conference devoted to providing private and micro-mid-cap biotechnology companies an opportunity to present…

13 December 2022

REVIVE Webinar: Influence of biological sex in infectious disease

REVIVE is a space for everybody with an interest in antimicrobial R&D.

22 November 2022

GARDP Webinar: Putting children first – Towards a better outcome for children and newborns with drug-resistant infections

REVIVE is a space for everybody with an interest in antimicrobial R&D.

22 November 2022

GARDP Webinar: Putting children first – Towards a better outcome for children and newborns with drug-resistant infections

The Global Antibiotic Research and Development Partnership (GARDP) is a Swiss not-for-profit organization developing new treatments for drug-resistant infections that…

17 November 2022

Emerging Antimicrobials and Diagnostics in AMR 2022 (EADA 2022)

EADA 2022 welcomes presenters from startups, SMEs, multinationals, academia and research institutions active in the domain of antibiotics, antimicrobials, alternative…

08 November 2022

REVIVE Webinar: Regulatory aspects of balancing benefits and risks in the clinical development of antibiotics

REVIVE is a space for everybody with an interest in antimicrobial R&D.

02 November 2022

Antimicrobial Resistance Digital Event

Act now: Incentives & Strategies to drive Innovation in the Antimicrobial Resistance Market.

24 October 2022

BIO-EUROPE 2022: FACILITATING GLOBAL PARTNERSHIPS THAT DRIVE LIFE SCIENCE DEALMAKING

BIO-Europe® is the preeminent partnering conference for the life sciences, bringing together international decision makers from the biotechnology, pharmaceutical and…

page 1/14